Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients

Last updated: February 17, 2026
Sponsor: The University of Texas Health Science Center, Houston
Overall Status: Active - Recruiting

Phase

2/3

Condition

Kidney Disease

Renal Failure

Kidney Failure

Treatment

Protonix (pantoprazole) 40 mg q 24 hrs for 2 days

Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days

Clinical Study ID

NCT06531642
HSC-MS-24-0411
175191
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The investigators propose a single-center, randomized, controlled trial to determine whether early initiation of proton pump inhibitor (PPI), pantoprazole, will decrease acute kidney injury (AKI) for trauma patients presenting with hemorrhagic shock compared to routine timing of initiation of PPI. Kidney injury will be assessed by the urinary kidney injury biomarkers, and the incidence, severity and AKI-free days within first week and major adverse kidney events (MAKE) at day 30. The specific aims of the study will be achieved by a cohort of 100 patients to receive either early(study) or routine (control) administration of pantoprazole for 2 days after the initial injury insult.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patient (≥18 years of age)

  • Patient meets hemorrhagic shock criteria:

  • Hypovolemic shock from traumatic acute bleeding

  • Systolic blood pressure ≤ 90 mmHg AND tachycardia (HR ≥ 108) at presentation to theED; OR

  • Systolic blood pressure ≤ 70 mmHg at presentation to the ED.

Exclusion

Exclusion Criteria:

  • Patients <18 years of age

  • Patients known to be actively on renal replacement therapy

  • Cardiac arrest prior to ED arrival or who are deemed to have expected survival ofless than 24 hours

  • History of PPI sensitivity or allergy

  • Patient who are already enrolled in other trials prior to ED arrival and thesetrials do not allow co-enrollment

  • Patient who presents with ongoing GI bleeding that will require higher dose of GIprophylaxis

  • Vulnerable populations such as pregnant women and prisoners

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Protonix (pantoprazole) 40 mg q 24 hrs for 2 days
Phase: 2/3
Study Start date:
September 07, 2024
Estimated Completion Date:
September 01, 2026

Study Description

Traumatic injuries account for 10% of all deaths globally and are the leading cause of mortality for trauma patients under 46 in the United States. Hemorrhage is the primary cause of death in both civilian and military trauma scenarios worldwide. Following hemorrhage and traumatic brain injury, organ failure, including acute kidney injury (AKI), is the third leading cause of death in trauma patients. AKI occurs in up to 50% of patients with hemorrhagic shock and is linked to increased morbidity, extended hospital stays, progression to chronic kidney disease, and higher short- and long-term mortality rates. Even patients with mild AKI, as classified by the RIFLE criteria (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease), face a 2.5 times higher risk of mortality. Battlefield conditions often delay access to definitive medical care for injured soldiers, highlighting the urgent need for effective shock treatments to minimize organ damage, such as AKI.

The investigators propose a single-center, randomized, controlled trial to determine whether early initiation of proton pump inhibitor (PPI), pantoprazole, will decrease acute kidney injury (AKI) for trauma patients presenting with hemorrhagic shock compared to routine timing of initiation of PPI.

Our study will include adults (over 18 years old) who meet the criteria for hemorrhagic shock, as these patients are more susceptible to hypoxic kidney damage due to bleeding and hypovolemia. This will allow us to assess whether early PPI initiation can better protect the kidneys during the early stages of hypoxic damage.

To evaluate this, the investigators will measure urinary kidney injury biomarkers in trauma patients to compare early pantoprazole initiation (study group) with the usual timing of PPI initiation (control group) (n=100, primary endpoint). Additionally, the investigators will assess whether early pantoprazole initiation decreases the incidence, severity, and number of AKI-free days within the first week post-hemorrhagic shock, as well as major adverse kidney events (MAKE: a composite of death, dialysis, renal hospitalization, or sustained kidney dysfunction) 30 days after the initial injury.

Connect with a study center

  • Memorial Hermann Texas Medical Center

    Houston, Texas 77030
    United States

    Site Not Available

  • Memorial Hermann Texas Medical Center

    Houston 4699066, Texas 4736286 77030
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.